Humabiologics, Inc is a regenerative medicine startup founded by scientists and tissue industry experts with scientific, quality, regulatory and technology transfer expertise to address the gap between the gift of donated human tissues and researchers. Currently, the availability of human-derived biomaterials for regenerative therapies and research is limited due to unstable supply channels, low quality, and high prices. Humabiologics is dedicated to extending the gift of donation by developing and commercializing high quality, supply-stable and affordable human-derived biomaterials from tissue and organs for regenerative medicine therapies that complies with the FDA's 21 CFR 1271 regulation and the tissue industry quality system standards. By stretching the gift of donation we strive to help as many people as possible with our unique product
We partner with academic and industry institutions to develop and provide affordable, supply-stable, and high quality human-derived biomaterials for researchers to innovate regenerative medicine therapies to address debilitating diseases and improve the quality of life for patients. Our products can be used alone or in conjunction with other biomaterials in various fields including tissue engineering, regenerative medicine, bio-printing, diagnostics & screening, pharmacology, cell culture, and many other life sciences applications.
We are dedicated to bridging the gap between the gift of donated human tissues and researchers. We strive to provide a high quality and stable supply of human-derived biomaterials at an affordable price to help researchers innovate regenerative medicine therapies to Empower Tomorrow's Innovations.
Our laboratory is able to help you define what you are working on and provide independent analysis you can use to verify your results.
We have over 20 years combined experience in navigating complex regulatory submissions to help you get from idea to approved therapies using biomaterials and human collagen.
We have decades of experiences in taking ideas from the bench-top to the market and scaling up manufacturing of complex products.
A $1 million seed funding is taking Humabiologics, Inc. closer to the market with its unique biomedical product. The Phoenix company, among the 2019 finalists in the BIO International Startup Stadium, is a regenerative medicine company founded by scientists and tissue industry experts.